HASSELT, Belgium, and CHEPSTOW, UK, 10 December 2018 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, announces that Non-Executive Director Dr Keith Martin and Chief Scientific Officer Prof David Wraith are scheduled to attend and present at the Antigen-Specific Immune Tolerance Europe 2018 conference being held in London on 10th-12th December. The conference will be held at Park Plaza Victoria.
Dr Martin and Dr Wraith’s presentation details are below.
11th December 2018
Presentation: Antigen-Specific Immunotherapy of Autoimmune Diseases
Presenter: David Wraith
The presentation is part of the session on ‘Harnessing Tregs to Induce Antigen-Specific Immune Tolerance’.
12th December 2018
Panel Discussion: Improving Pre-Clinical Predictability of Antigen-Specific Immune Tolerance Therapies
Dr Keith Martin to join panel discussion along with Timm Jessen, Topas Therapeutics and Pieter Rottiers, ActoBio Therapeutics. The panel is part of the session on ‘Overcoming Translational Challenges of Antigen-Specific Immune Tolerance Therapies into the Clinic’.
Presentation: Antigen Specific Immunotherapy with Apitopes® from Concept to Clinic”
Presenter: Dr Keith Martin
The presentation is part of the session on ‘Optimizing Clinical Development & Paving the Future of Antigen-Specific Immune Tolerance Therapies’.
Antigen-Specific Immune Tolerance Europe 2018 is the first European centric, dedicated platform that brings key decision makers together to successfully translate ground breaking science into a novel class of therapies to treat autoimmunity. The Conference will be will be dedicated to determining novel antigen identification, validation of preclinical models and ultimately the effective clinical translation of this research clinical setting.